SEXUAL AROUSAL, SEXUAL DESIRE, ORGASM AND/OR PLEASURE FOLLOWING INTRAVAGINAL PRASTERONE (DHEA) ADMINISTRATION IN WOMEN NOT SUFFERING OR INDEPENDENTLY FROM DYSPAREUNIA OR OTHER SYMPTOMS OF VULVO-VAGINAL ATROPHY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Feb 13, 2014
app pub date -
Jul 16, 2013
filing date -
Jul 25, 2012
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorder, female orgasm disorder and female sexual interest arousal disorder in a woman who either (1) is not suffering from symptoms of vulvo-vaginal atrophy and/or (2) is not suffering from moderate to severe dyspareunia.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully